Symbols / ABVC Stock $1.05 -1.87% ABVC BioPharma, Inc.

Healthcare • Biotechnology • United States • NCM
ABVC (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Uttam Yashwant Patil Ph.D.
Exch · Country NCM · United States
Market Cap 26.92M
Enterprise Value 31.35M
Income -7.91M
Sales —
FCF (ttm) 721.90K
Book/sh 0.46
Cash/sh 0.03
Employees 16
Insider 10d —
IPO Nov 10, 2004
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.39
PEG —
P/S —
P/B 2.30
P/C —
EV/EBITDA -4.40
EV/Sales —
Quick Ratio 0.12
Current Ratio 0.41
Debt/Eq 26.12
LT Debt/Eq —
EPS (ttm) -0.39
EPS next Y -0.44
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2023-05-15
Earnings (prior) 2023-05-15
ROA -31.25%
ROE -119.49%
ROIC —
Gross Margin 0.00%
Oper. Margin 3.76%
Profit Margin 0.00%
Shs Outstand 25.64M
Shs Float 19.88M
Insider Own 18.98%
Instit Own 3.40%
Short Float 1.42%
Short Ratio 2.36
Short Interest 295.27K
52W High 5.48
vs 52W High -80.84%
52W Low 0.88
vs 52W Low 19.32%
Beta 0.38
Impl. Vol. 0.00%
Rel Volume 0.46
Avg Volume 87.30K
Volume 40.51K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $1.07
Price $1.05
Change -1.87%
About

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$1.05
Latest analyst target
3. DCF / Fair value
$0.51
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.05
Low
—
High
—
Mean
—
News
RSS: Latest ABVC news

No recent news from Yahoo. Try the RSS feed for latest ABVC news.

Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
-100.00%
0.51
+234.31%
0.15
-84.28%
0.97
Operating Revenue
0.00
-100.00%
0.51
+234.31%
0.15
-84.28%
0.97
Cost Of Revenue
0.00
-100.00%
0.00
-99.75%
0.30
+5.45%
0.29
Reconciled Cost Of Revenue
0.00
-100.00%
0.00
-99.75%
0.30
+5.45%
0.29
Gross Profit
0.00
-100.00%
0.51
+440.11%
-0.15
-121.89%
0.68
Operating Expense
7.15
+37.15%
5.21
-21.20%
6.62
-58.11%
15.80
Research And Development
0.12
-32.46%
0.18
-83.13%
1.06
-60.54%
2.69
Selling General And Administration
7.03
+39.63%
5.03
-9.35%
5.55
-57.62%
13.10
General And Administrative Expense
7.03
+39.63%
5.03
-9.35%
5.55
-57.62%
13.10
Salaries And Wages
4.14
+49.37%
2.77
+1391.64%
0.19
-97.36%
7.04
Other Gand A
2.89
+27.68%
2.26
-57.88%
5.37
-11.52%
6.07
Other Operating Expenses
—
—
—
—
Total Expenses
7.15
+37.13%
5.21
-24.63%
6.92
-56.98%
16.08
Operating Income
-7.15
-51.98%
-4.71
+30.47%
-6.77
+55.23%
-15.11
Total Operating Income As Reported
-7.15
-51.98%
-4.71
+30.47%
-6.77
+55.23%
-15.11
EBITDA
-7.43
-71.14%
-4.34
+31.40%
-6.33
+58.34%
-15.20
Normalized EBITDA
-6.36
-50.18%
-4.23
+30.95%
-6.13
+58.63%
-14.82
Reconciled Depreciation
0.50
+151.26%
0.20
-47.18%
0.38
+1498.34%
0.02
EBIT
-7.94
-74.68%
-4.54
+32.30%
-6.71
+55.91%
-15.22
Total Unusual Items
-1.07
-887.28%
-0.11
+45.42%
-0.20
+47.17%
-0.38
Total Unusual Items Excluding Goodwill
-1.07
-887.28%
-0.11
+45.42%
-0.20
+47.17%
-0.38
Special Income Charges
-0.80
-414.18%
0.26
0.00
+100.00%
-0.11
Other Special Charges
—
-0.26
—
—
Write Off
0.80
0.00
0.00
-100.00%
0.11
Net Income
-7.91
-61.30%
-4.90
+37.05%
-7.79
+52.58%
-16.42
Pretax Income
-8.35
-55.56%
-5.37
+33.09%
-8.02
+48.28%
-15.51
Net Non Operating Interest Income Expense
-0.25
+66.31%
-0.74
+34.54%
-1.13
-962.82%
-0.11
Interest Expense Non Operating
0.42
-49.64%
0.83
-37.13%
1.31
+346.88%
0.29
Net Interest Income
-0.25
+66.31%
-0.74
+34.54%
-1.13
-962.82%
-0.11
Interest Expense
0.42
-49.64%
0.83
-37.13%
1.31
+346.88%
0.29
Interest Income Non Operating
0.17
+91.29%
0.09
-52.90%
0.19
-1.24%
0.19
Interest Income
0.17
+91.29%
0.09
-52.90%
0.19
-1.24%
0.19
Other Income Expense
-0.95
-1383.92%
0.07
+157.12%
-0.13
+55.82%
-0.29
Other Non Operating Income Expenses
0.12
-34.10%
0.18
+164.02%
0.07
-16.53%
0.08
Gain On Sale Of Security
-0.27
+25.80%
-0.36
-82.89%
-0.20
+25.37%
-0.27
Tax Provision
0.02
+121.85%
-0.11
-143.18%
0.26
-67.91%
0.80
Tax Rate For Calcs
0.00
+920.11%
0.00
-90.20%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-0.23
-9971.28%
-0.00
+94.65%
-0.04
+47.17%
-0.08
Net Income Including Noncontrolling Interests
-8.38
-59.29%
-5.26
+36.49%
-8.28
+49.24%
-16.31
Net Income From Continuing Operation Net Minority Interest
-7.91
-61.30%
-4.90
+37.05%
-7.79
+52.58%
-16.42
Net Income From Continuing And Discontinued Operation
-7.91
-61.30%
-4.90
+37.05%
-7.79
+52.58%
-16.42
Net Income Continuous Operations
-8.38
-59.29%
-5.26
+36.49%
-8.28
+49.24%
-16.31
Minority Interests
0.47
+31.52%
0.36
-27.73%
0.49
+544.50%
-0.11
Normalized Income
-7.06
-47.21%
-4.80
+37.14%
-7.63
+52.68%
-16.13
Net Income Common Stockholders
-7.91
-61.30%
-4.90
+37.05%
-7.79
+52.58%
-16.42
Diluted EPS
—
-0.42
+76.67%
-1.80
+65.38%
-5.20
Basic EPS
—
-0.42
+76.67%
-1.80
+65.38%
-5.20
Basic Average Shares
—
11.67
+169.26%
4.34
+36.92%
3.17
Diluted Average Shares
—
11.67
+169.26%
4.34
+36.92%
3.17
Diluted NI Availto Com Stockholders
-7.91
-61.30%
-4.90
+37.05%
-7.79
+52.58%
-16.42
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
21.06
+179.34%
7.54
-3.14%
7.78
-18.74%
9.58
Current Assets
2.50
+14.75%
2.18
+31.58%
1.66
-44.54%
2.99
Cash Cash Equivalents And Short Term Investments
0.75
+138.20%
0.31
+124.51%
0.14
-13.41%
0.16
Cash And Cash Equivalents
0.68
+174.37%
0.25
+312.90%
0.06
-29.45%
0.09
Other Short Term Investments
0.06
-0.59%
0.06
-18.38%
0.08
+4.64%
0.08
Receivables
0.76
-33.91%
1.16
+52.07%
0.76
-44.54%
1.37
Accounts Receivable
—
0.00
-100.00%
0.00
-98.44%
0.10
Gross Accounts Receivable
—
0.62
-0.26%
0.62
—
Allowance For Doubtful Accounts Receivable
—
-0.62
+0.01%
-0.62
—
Inventory
—
—
—
0.00
Raw Materials
—
—
—
0.00
Work In Process
—
—
—
0.00
Finished Goods
—
—
—
0.00
Prepaid Assets
—
—
—
—
Restricted Cash
0.65
+4.89%
0.62
-6.27%
0.66
-49.74%
1.31
Other Current Assets
0.35
+260.26%
0.10
-4.79%
0.10
-32.74%
0.15
Total Non Current Assets
18.56
+246.28%
5.36
-12.53%
6.13
-7.05%
6.59
Net PPE
14.75
+1180.85%
1.15
-16.47%
1.38
-20.55%
1.74
Gross PPE
18.13
+303.47%
4.49
-4.68%
4.71
-6.47%
5.04
Accumulated Depreciation
-3.38
-1.15%
-3.34
-0.20%
-3.34
-0.93%
-3.30
Properties
0.00
0.00
0.00
0.00
Land And Improvements
12.69
+3642.46%
0.34
-6.73%
0.36
+0.62%
0.36
Buildings And Improvements
2.22
+0.22%
2.22
-0.37%
2.23
+0.03%
2.23
Machinery Furniture Equipment
1.31
+0.86%
1.29
-1.44%
1.31
+1.78%
1.29
Construction In Progress
—
—
7.40
0.00
Other Properties
1.91
+198.77%
0.64
-20.87%
0.81
-30.30%
1.16
Goodwill And Other Intangible Assets
—
—
—
—
Goodwill
—
—
—
—
Investments And Advances
1.88
-16.84%
2.26
-10.64%
2.53
+200.18%
0.84
Long Term Equity Investment
1.85
+25.96%
1.47
-12.61%
1.68
0.00
Other Investments
—
—
0.85
+0.62%
0.84
Non Current Accounts Receivable
—
—
0.11
-86.88%
0.87
Non Current Deferred Assets
—
—
0.00
-100.00%
0.12
Non Current Deferred Taxes Assets
—
—
0.00
-100.00%
0.12
Non Current Prepaid Assets
1.82
+0.00%
1.82
-7.63%
1.97
-35.15%
3.03
Other Non Current Assets
0.12
-12.14%
0.13
-5.74%
0.14
—
Total Liabilities Net Minority Interest
7.76
+13.92%
6.82
+4.36%
6.53
+2.96%
6.34
Current Liabilities
6.16
-6.00%
6.56
+7.47%
6.10
+10.07%
5.54
Payables And Accrued Expenses
2.36
-12.45%
2.70
+14.42%
2.36
+5.71%
2.23
Payables
0.12
-84.78%
0.77
+169.88%
0.29
-20.43%
0.36
Accounts Payable
—
—
—
—
Current Accrued Expenses
2.25
+16.56%
1.93
-7.05%
2.07
+10.74%
1.87
Pensionand Other Post Retirement Benefit Plans Current
1.45
+25.44%
1.15
+9.99%
1.05
+84.12%
0.57
Total Tax Payable
0.01
0.00
-100.00%
0.11
0.00
Current Debt And Capital Lease Obligation
1.87
-14.67%
2.19
+0.29%
2.19
-3.33%
2.26
Current Debt
1.55
-13.17%
1.79
+0.25%
1.79
-5.70%
1.89
Other Current Borrowings
0.80
-15.90%
0.95
+7.17%
0.89
—
Current Capital Lease Obligation
0.32
-21.32%
0.40
+0.44%
0.40
+8.80%
0.37
Current Deferred Liabilities
0.01
-84.47%
0.08
+2.03%
0.08
+623.71%
0.01
Current Deferred Revenue
0.01
-84.47%
0.08
+2.03%
0.08
+623.71%
0.01
Other Current Liabilities
0.47
+9.31%
0.43
+0.65%
0.43
-8.72%
0.47
Total Non Current Liabilities Net Minority Interest
1.60
+519.28%
0.26
-39.77%
0.43
-46.34%
0.80
Long Term Debt And Capital Lease Obligation
1.60
+575.97%
0.24
-41.88%
0.41
-48.54%
0.79
Long Term Capital Lease Obligation
1.60
+575.97%
0.24
-41.88%
0.41
-48.54%
0.79
Other Non Current Liabilities
—
0.02
+0.00%
0.02
+171.71%
0.01
Stockholders Equity
11.11
+806.25%
1.23
-21.10%
1.55
-49.84%
3.10
Common Stock Equity
11.11
+806.25%
1.23
-21.10%
1.55
-49.84%
3.10
Capital Stock
0.03
+80.65%
0.01
+74.66%
0.01
+141.63%
0.00
Common Stock
0.03
+80.65%
0.01
+74.66%
0.01
+141.63%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
25.05
+80.65%
13.87
+74.66%
7.94
+139.65%
3.31
Ordinary Shares Number
24.32
+85.13%
13.14
+66.01%
7.91
+140.85%
3.29
Treasury Shares Number
0.73
+0.00%
0.73
+2651.63%
0.03
-3.56%
0.03
Additional Paid In Capital
96.01
+22.16%
78.60
+6.24%
73.98
+8.89%
67.94
Retained Earnings
-76.86
-11.47%
-68.95
-7.66%
-64.05
-16.65%
-54.90
Gains Losses Not Affecting Retained Earnings
0.49
+9.41%
0.45
-13.70%
0.52
-0.14%
0.52
Treasury Stock
8.91
+0.00%
8.91
+0.09%
8.90
-2.18%
9.10
Minority Interest
2.19
+535.23%
-0.50
-67.04%
-0.30
-318.56%
0.14
Other Equity Adjustments
0.49
+9.41%
0.45
-13.70%
0.52
-0.14%
0.52
Total Equity Gross Minority Interest
13.30
+1736.77%
0.72
-42.24%
1.25
-61.27%
3.24
Total Capitalization
11.11
+806.25%
1.23
-21.10%
1.55
-49.84%
3.10
Working Capital
-3.66
+16.33%
-4.38
+1.52%
-4.45
-73.89%
-2.56
Invested Capital
12.67
+319.91%
3.02
-9.68%
3.34
-33.10%
4.99
Total Debt
3.47
+42.87%
2.43
-6.33%
2.60
-15.05%
3.05
Net Debt
0.87
-43.38%
1.54
-10.65%
1.73
-4.58%
1.81
Capital Lease Obligations
1.92
+199.55%
0.64
-20.87%
0.81
-30.30%
1.16
Net Tangible Assets
11.11
+806.25%
1.23
-21.10%
1.55
-49.84%
3.10
Tangible Book Value
11.11
+806.25%
1.23
-21.10%
1.55
-49.84%
3.10
Available For Sale Securities
0.03
-96.36%
0.79
-6.73%
0.85
+0.62%
0.84
Current Notes Payable
0.03
+0.00%
0.03
0.00
—
Duefrom Related Parties Current
0.76
-33.91%
1.16
+52.37%
0.76
-40.37%
1.27
Duefrom Related Parties Non Current
—
0.00
-100.00%
0.11
-86.88%
0.87
Dueto Related Parties Current
0.11
-86.33%
0.77
+345.58%
0.17
-51.81%
0.36
Inventories Adjustments Allowances
—
—
—
0.00
Investmentin Financial Assets
0.03
-96.36%
0.79
-6.73%
0.85
+0.62%
0.84
Investmentsin Associatesat Cost
1.85
+25.96%
1.47
-12.61%
1.68
0.00
Investmentsin Joint Venturesat Cost
0.00
0.00
—
—
Line Of Credit
0.73
-10.46%
0.81
-9.90%
0.90
-52.51%
1.89
Other Equity Interest
0.36
+1056.57%
0.03
+106.88%
-0.45
+66.67%
-1.35
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-2.99
-65.07%
-1.81
+56.79%
-4.19
+43.41%
-7.40
Cash Flow From Continuing Operating Activities
-2.99
-65.07%
-1.81
+56.79%
-4.19
+43.41%
-7.40
Net Income From Continuing Operations
-8.38
-59.29%
-5.26
+36.49%
-8.28
+49.24%
-16.31
Depreciation Amortization Depletion
0.50
+151.26%
0.20
-47.18%
0.38
+1498.34%
0.02
Depreciation
0.50
+151.26%
0.20
-47.18%
0.38
+1498.34%
0.02
Depreciation And Amortization
0.50
+151.26%
0.20
-47.18%
0.38
+1498.34%
0.02
Other Non Cash Items
0.35
-34.10%
0.53
-57.18%
1.24
+3746.20%
0.03
Stock Based Compensation
4.14
+49.37%
2.77
+1391.64%
0.19
-97.36%
7.04
Provisionand Write Offof Assets
0.00
-100.00%
0.01
-99.18%
1.46
+591.05%
0.21
Asset Impairment Charge
0.81
0.00
0.00
-100.00%
0.11
Deferred Tax
—
0.00
-100.00%
0.12
-86.62%
0.86
Deferred Income Tax
—
0.00
-100.00%
0.12
-86.62%
0.86
Operating Gains Losses
0.19
-43.17%
0.34
+52.86%
0.22
—
Gain Loss On Investment Securities
0.19
-43.17%
0.34
+52.86%
0.22
—
Change In Working Capital
-0.62
-50.65%
-0.41
-183.22%
0.49
-22.78%
0.64
Change In Receivables
-0.14
+53.57%
-0.29
-215.35%
-0.09
+93.58%
-1.45
Changes In Account Receivables
—
0.00
-100.00%
0.23
+137.21%
-0.61
Change In Inventory
-0.01
0.00
—
0.00
Change In Prepaid Assets
-0.07
-653.39%
0.01
-87.30%
0.10
-57.19%
0.24
Change In Payables And Accrued Expense
0.16
+311.73%
0.04
-94.70%
0.75
-59.39%
1.85
Change In Accrued Expense
0.15
-0.40%
0.15
-76.08%
0.64
-60.30%
1.61
Change In Payable
0.01
+110.59%
-0.11
-200.00%
0.11
-53.42%
0.24
Change In Account Payable
—
—
—
0.00
Change In Other Working Capital
-0.09
-5386.69%
0.00
-98.04%
0.08
+3262.12%
-0.00
Change In Other Current Liabilities
-0.47
-180.93%
-0.17
+52.00%
-0.35
-13433.04%
-0.00
Investing Cash Flow
-1.21
0.00
+100.00%
-0.36
+79.08%
-1.72
Cash Flow From Continuing Investing Activities
-1.21
0.00
+100.00%
-0.36
+79.08%
-1.72
Net PPE Purchase And Sale
—
0.00
+100.00%
-0.02
+82.29%
-0.12
Purchase Of PPE
—
0.00
+100.00%
-0.02
+82.29%
-0.12
Capital Expenditure
—
—
-0.02
+82.29%
-0.12
Net Investment Purchase And Sale
—
—
—
0.00
Purchase Of Investment
—
—
—
0.00
Sale Of Investment
—
—
—
—
Net Business Purchase And Sale
—
0.00
+100.00%
-0.34
+78.84%
-1.60
Purchase Of Business
—
0.00
+100.00%
-0.34
+78.84%
-1.60
Net Other Investing Changes
-1.20
—
—
—
Financing Cash Flow
4.64
+134.15%
1.98
-48.82%
3.87
-3.59%
4.01
Cash Flow From Continuing Financing Activities
4.64
+134.15%
1.98
-48.82%
3.87
-3.59%
4.01
Net Issuance Payments Of Debt
0.34
+2043.20%
0.02
-96.56%
0.46
+32.18%
0.35
Issuance Of Debt
0.89
+138.92%
0.37
-74.56%
1.46
+317.89%
0.35
Repayment Of Debt
-0.55
-53.77%
-0.36
+64.38%
-1.00
0.00
Long Term Debt Issuance
0.39
+1200.00%
0.03
0.00
0.00
Long Term Debt Payments
-0.43
-30.66%
-0.33
0.00
0.00
Net Long Term Debt Issuance
-0.04
+87.45%
-0.30
0.00
0.00
Short Term Debt Issuance
0.50
+45.87%
0.34
-76.61%
1.46
+317.89%
0.35
Short Term Debt Payments
-0.12
-313.01%
-0.03
+97.08%
-1.00
0.00
Net Short Term Debt Issuance
0.38
+20.98%
0.31
-32.35%
0.46
+32.18%
0.35
Net Common Stock Issuance
3.31
+13834.67%
0.02
-97.74%
1.05
-71.34%
3.66
Common Stock Payments
0.00
+100.00%
-0.01
0.00
—
Repurchase Of Capital Stock
0.00
+100.00%
-0.01
0.00
—
Proceeds From Stock Option Exercised
0.99
-26.10%
1.34
-44.25%
2.41
0.00
Net Other Financing Charges
—
0.60
+1323.60%
-0.05
—
Changes In Cash
0.44
+158.07%
0.17
+125.35%
-0.68
+86.74%
-5.11
Effect Of Exchange Rate Changes
0.02
+182.41%
-0.02
-1257.13%
0.00
+103.16%
-0.07
Beginning Cash Position
0.86
+20.51%
0.72
-48.50%
1.39
-78.80%
6.57
End Cash Position
1.33
+53.62%
0.86
+20.51%
0.72
-48.50%
1.39
Free Cash Flow
-2.99
-65.07%
-1.81
+57.01%
-4.21
+44.03%
-7.52
Interest Paid Supplemental Data
0.03
+39.84%
0.02
-32.07%
0.03
-88.38%
0.29
Income Tax Paid Supplemental Data
0.01
-53.30%
0.03
-5.58%
0.03
+1612.00%
0.00
Change In Income Tax Payable
0.01
+110.59%
-0.11
-200.00%
0.11
0.00
Change In Interest Payable
—
—
—
-0.00
Change In Tax Payable
0.01
+110.59%
-0.11
-200.00%
0.11
0.00
Common Stock Issuance
3.31
+10548.53%
0.03
-97.04%
1.05
-71.34%
3.66
Issuance Of Capital Stock
3.31
+10548.53%
0.03
-97.04%
1.05
-71.34%
3.66
Net Investment Properties Purchase And Sale
-0.01
0.00
—
—
Purchase Of Investment Properties
-0.01
0.00
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category